Institutional investors purchased a net $24.3 million shares of TXMD during the quarter ended March 2016. This may signal that the smart money is gaining interest in this company as the 78.76% of shares outstanding that institutional investors hold is actually below the Pharmaceuticals: Generic industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 10.5 Million shares of TherapeuticsMD Inc
JPMORGAN ASSET MANAGEMENT (UK) L... Bought 3.1 Million shares of TherapeuticsMD Inc
FIDELITY MANAGEMENT & RESEARCH C... Bought 2.7 Million shares of TherapeuticsMD Inc